The prognosis of adult patients with Ph chromosomepositive ALL (Ph þ ALL) is considered poor with an expected long-term survival of 20% at 10 years while no patients with less than a 3-log reduction in BCR-ABL transcripts were alive at 2 years. 1 The combination of imatinib with chemotherapy in the induction therapy regimen had improved the response rate, but had not affected overall survival. 2 Allo-SCT is still considered the treatment of choice in adults with this disease, despite the fact that post-SCT relapses are relatively frequent. 3 A second allotransplant is rarely successful. Administration of imatinib early after SCT might be an effective approach to prevent recurrence of Ph þ ALL, but its feasibility has not been systematically evaluated. 4 Second generationtargeted therapies, such as nilotinib (Novartis) and dasatinib (Bristol-Myers Squibb), have been evaluated for Ph þ ALL. 5 Nilotinib monotherapy exhibits clinical activity in patients with relapsed/refractory Ph þ ALL with 26% achieving complete hematologic response (median treatment duration 1.8 months) 6 while 31% achieved complete hematologic response with dasatinib (follow-up 6 months).
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A 36-year-old woman with Ph þ ALL, who was M-BCR-and m-BCR-positive and karyotype 46, XX, t(9;22) in 20/20 (100%) of metaphases analyzed without additional anomalies, received induction therapy according to the HyperCVAD regimen (hyperfractionated CY, VCR, doxorubicin and dexamethasone) in combination with imatinib mesylate 400 mg twice daily (BID). 2 The hematologic and clinical outcome is described in Table 1 . The patient developed early meningeal leukemia with a high blast count (18 Â 10 9 /l) that was treated by intrathecal MTX once a week for 6 weeks. After 3 weeks, she achieved complete hematologic response with persistence of M-BCR transcript at a value of 2.5% on quantitative PCR analysis; 8 this percentage was actually a BCR-ABL/ABL ratio, calibrated on K562 cell line and not normalized to the international scale. On 30 June 2006, she received a sibling donor unmanipulated BM stem cell transplant after 12 Gy TBI in six fractions plus CY given by 1 h infusion of 60 mg/kg/die Â 2 days; acute GVHD prophylaxis consisted of CYA and MTX. Complete hemopoietic recovery was observed on Day þ 18 after transplant. No evidence of acute GVHD or infection was observed during the early transplant period. On Day þ 100, the patient was in complete response with a complete donor chimera confirmed by Gene Mapper Analysis (3130xl ABI Prism) on DNA extracted using a commercial kit. The BM M-BCR transcripts were positive at 0.025%. Leukemia relapse was documented 6 months later. At the time of relapse, the PCR was positive for M-BCR and m-BCR transcripts and karyotyping analysis showed additional anomalies. CYA was interrupted following relapse but no acute GVHD developed. She received no donor lymphocyte infusions. The patient was treated with idarubicin (15 mg per day on days 1 and 3) plus cytarabine (4500 mg/12 h for 3 days) but did not achieve any response. She was then treated with i.v. VCR 2 mg once a week for 2 weeks and dexamethasone 40 mg 4 days a week for 4 weeks. In addition, she received imatinib 400 mg BID over 28 days according to a modified regimen consisting of high-dose imatinib combined with VCR and dexamethasone. 9 The patient achieved hematologic remission with persistence of M-BCR positivity and a mixed chimerism. Sequencing analysis of reverse transcriptase-PCR product found no BCR-ABL mutations. The patient was thus enrolled in a compassionate use protocol with nilotinib (Novartis). Nilotinib was initiated at standard dose 400 mg BID; after 6 months there was a dose reduction to 200 mg BID because of recurrent episodes of acute bronchitis and gastritis. The patient was treated with fluconazole and ciprofloxacin for Candida albicans and Pseudomonas aeruginosa infections detected by bronchoscopy and sputum culture. There was no interruption of nilotinib therapy. BM and chimerism were assessed on days 15 and 28 of the first cycle, and on day 28 of every even-numbered cycle. The patient was evaluated for cytogenetics at baseline and in repeated analyses. Safety assessments included an evaluation of adverse events, hematologic and cardiac enzyme assessments, biochemical testing, urinalysis, electrocardiography and physical examination. The treatment was well tolerated. She obtained a complete molecular remission, defined as PCR negativity of both M-BCR and m-BCR (confirmed by nested PCR), and her BM showed a complete chimera of the donor. At present, she is still in complete response with a full-donor chimerism 28 months after relapse and remains on nilotinib therapy at a dose of 200 mg BID.
Imatinib given early after a high-dose chemotherapy regimen might be effective for preventing relapse after allogeneic transplantation in Ph þ ALL patients. However, the feasibility of this approach is still under investigation. 4 There are no reports that the use of imatinib, dasatinib or nilotinib induces long-term remission in post allogeneic transplant Ph þ ALL patients after relapse. As far as we know, this is the first case of CR achieved in a post allogeneic transplant Ph þ ALL patient after relapse, who was resistant to several cycles of combination therapy with chemotherapy and imatinib. Interestingly, our patient achieved molecular remission after 1 month of nilotinib therapy. Nilotinib is a rationally designed aminopyrimidine inhibitor of BCR-ABL tyrosine kinase; it is 30-fold more potent than imatinib against BCR-ABL in vitro and in mouse models. 10 Our case suggests that nilotinib is a novel treatment option for patients with relapsed/refractory Ph þ ALL after allo-SCT. However, the question of 'more TK inhibition-less chemotherapy' would be better addressed in a prospective trial using an alternative regimen of tyrosine kinase inhibitors. Our patient obtained a durable cytogenetic response associated with reconstitution of fulldonor chimerism without any signs of GVHD. We suggest that nilotinib can be safely administered after allo-SCT relapse. It may help prevent the re-emergence of Ph þ clone and restore full-donor hematopoiesis in the context of a nonaggressive therapeutic regimen.
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